Evidence map›Paper›PMID 38886527›Full record

ArticleScientific reports2024

N-butyl-β-carboline-3-carboxylate (β-CCB) systemic administration promotes remyelination in the cuprizone demyelinating model in mice.

Fidel Vélez-Uriza, Rainald Pablo Ordaz, Edith Garay, Abraham J Cisneros-Mejorado, Rogelio O Arellano

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Advances in Therapeutics Research for Demyelinating Diseases.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fidel Vélez-UrizaInstituto de Neurobiología, Laboratorio de Neurofisiología Celular, Universidad Nacional Autónoma de México, Boulevard Juriquilla 3001, Juriquilla Querétaro, C.P. 76230, México.
Rainald Pablo OrdazInstituto de Neurobiología, Laboratorio de Neurofisiología Celular, Universidad Nacional Autónoma de México, Boulevard Juriquilla 3001, Juriquilla Querétaro, C.P. 76230, México.
Edith GarayInstituto de Neurobiología, Laboratorio de Neurofisiología Celular, Universidad Nacional Autónoma de México, Boulevard Juriquilla 3001, Juriquilla Querétaro, C.P. 76230, México.
Abraham J Cisneros-MejoradoInstituto de Neurobiología, Laboratorio de Neurofisiología Celular, Universidad Nacional Autónoma de México, Boulevard Juriquilla 3001, Juriquilla Querétaro, C.P. 76230, México. acisneros@conahcyt.mx.
Rogelio O ArellanoInstituto de Neurobiología, Laboratorio de Neurofisiología Celular, Universidad Nacional Autónoma de México, Boulevard Juriquilla 3001, Juriquilla Querétaro, C.P. 76230, México. arellano.ostoa@comunidad.unam.mx.

Funding

CONAHCYT CF-1771CONAHCYT CF-319740CONAHCYT CVU: 700811CONAHCYT CVU: 857777PAPIIT-UNAM-México PAPIIT-No. IN205822
6 · The paper itself

Abstract

Demyelination is generated in several nervous system illnesses. Developing strategies for effective clinical treatments requires the discovery of promyelinating drugs. Increased GABAergic signaling through γ-aminobutyric acid type A receptor (GABA

Indexed as

CarbolinesCuprizoneDemyelinating DiseasesDisease Models, AnimalRemyelinationAnimalsMagnetic Resonance ImagingMaleMiceMice, Inbred C57BLMultiple SclerosisMyelin SheathOligodendrogliaWhite MatterCarbolinesCuprizoneCuprizoneGABAMRIOligodendrocyteRemyelinationβ-Carboline

Identifiers

PMID38886527
PMCPMC11183054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.